EVOEvotec SE

Nasdaq evotec.com


$ 3.76 $ 0.06 (1.62 %)    

Friday, 30-Aug-2024 15:55:25 EDT
QQQ $ 476.00 $ 5.61 (1.19 %)
DIA $ 416.44 $ 2.30 (0.56 %)
SPY $ 563.62 $ 5.33 (0.95 %)
TLT $ 96.60 $ -1.04 (-1.07 %)
GLD $ 231.30 $ -1.66 (-0.71 %)
$ 3.77
$ 3.71
$ 3.75 x 100
-- x --
$ 3.71 - $ 3.77
$ 2.85 - $ 12.40
41,515
na
334M
$ 0.94
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-maintains-buy-on-evotec-lowers-price-target-to-8

HC Wainwright & Co. analyst Douglas Tsao maintains Evotec (NASDAQ:EVO) with a Buy and lowers the price target from $11 t...

 bristol-myers-german-partner-evotec-plans-layoffs-cites-challenging-revenues-profitability

Evotec reports a rise in Q2 sales to $201.12M but posts an EPS loss of $0.54. CEO Christian Wojczewski cites market challenges ...

 evotec-2024-outlook-expects-revenues-of-790m-820m-and-adjusted-group-ebitda-of-15m-35m

REFINED BUSINESS OUTLOOK FOR FULL-YEAR 2024    

Core News & Articles

Key scientific achievements drive the expansion of the pipeline of molecular glue degraders Performance-based and prog...

Core News & Articles

Key scientific achievement advances the joint neuroscience pipeline and earns a payment of US$ 25 m to Evotec to progress furth...

Core News & Articles

Multi-year collaboration will initially focus on early discovery research for metabolic and infectious diseases The re...

 german-drug-developer-evotec-seeks-adviser-input-as-takeover-concerns-mount

Evotec consults defense advisers following a significant share price decline, raising concerns about a potential takeover.

 evotec-consults-defense-advisers-following-share-selloff-amid-takeover-concerns-several-buyout-firms-evaluating-company-and-drug-pipeline-incoming-ceo-christian-wojczewski-to-assess-situation-before-strategic-decisions

- Bloomberg

 evotec-joins-forces-with-inserm-and-lille-university-hospital-to-identify-key-mechanisms-in-obesity-and-metabolic-diseases

Partnership will expand Evotec's molecular patient database in the area of metabolic diseases and in particular obesity ...

 hc-wainwright--co-reiterates-buy-on-evotec-maintains-11-price-target

HC Wainwright & Co. analyst Douglas Tsao reiterates Evotec (NASDAQ:EVO) with a Buy and maintains $11 price target.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION